An updated literature on BRAF inhibitors (2018–2023)Lalmohan Maji, Gurubasavaraja Swamy Purawarga Matada, Sindhuja Sengupta et al.|Molecular Diversity|2023Cited by 24
Pharmacophore modeling, virtual screening, molecular docking and dynamics studies for the discovery of HER2-tyrosine kinase inhibitors: An in-silico approachGurubasavaraja Swamy Purawarga Matada, Nulgumnalli Manjunathaiah Raghavendra, Nahid Abbas et al.|Journal of Molecular Structure|2022Cited by 17
Molecular recognition of some novel mTOR kinase inhibitors to develop anticancer leads by drug-likeness, molecular docking and molecular dynamics based virtual screening strategyArka Das, Ganesh Prasad Shenoy, Nahid Abbas et al.|Computational Toxicology|2022Cited by 12
Current updates on EGFR and HER2 tyrosine kinase inhibitors for the breast cancerPrasad Sanjay Dhiwar, Pujan Sasmal, Nulgumnalli Manjunathaiah Raghavendra et al.|Medicinal Chemistry Research|2022Cited by 8